"The product is an anti-herpes virus agent with a novel mechanism of action created by Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo, President and CEO: Yoshihiko Hatanaka). The product has been observed to inhibit the proliferation of the varicella-zoster virus (hereinafter VZV) by inhibiting the activity of the helicase-primase complex, which is essential for viral DNA replication. […]The product is proven to be effective against VZV when administered once a day after meals. […] General administration for adults is 400mg of amenamevir once a day administered orally after a meal"
https://www.maruho.co.jp/english/release/nek5p40000001vpv-att/20170703_pr_eng.pdf
https://www.maruho.co.jp/english/release/nek5p40000001vpv-att/20170703_pr_eng.pdf